- Home
- TOP vs MURA Comparison
TOP vs MURA Comparison
Compare TOP & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- MURA
- Stock Information
- Founded
- TOP 2015
- MURA 2013
- Country
- TOP Singapore
- MURA Ireland
- Employees
- TOP N/A
- MURA N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- MURA
- Sector
- TOP Finance
- MURA
- Exchange
- TOP Nasdaq
- MURA Nasdaq
- Market Cap
- TOP 43.0M
- MURA 36.0M
- IPO Year
- TOP 2022
- MURA N/A
- Fundamental
- Price
- TOP $1.03
- MURA $2.09
- Analyst Decision
- TOP
- MURA Buy
- Analyst Count
- TOP 0
- MURA 2
- Target Price
- TOP N/A
- MURA $6.00
- AVG Volume (30 Days)
- TOP 60.9K
- MURA 106.7K
- Earning Date
- TOP 08-13-2025
- MURA 11-06-2025
- Dividend Yield
- TOP N/A
- MURA N/A
- EPS Growth
- TOP N/A
- MURA N/A
- EPS
- TOP N/A
- MURA N/A
- Revenue
- TOP $3,329,256.00
- MURA N/A
- Revenue This Year
- TOP N/A
- MURA N/A
- Revenue Next Year
- TOP N/A
- MURA N/A
- P/E Ratio
- TOP N/A
- MURA N/A
- Revenue Growth
- TOP N/A
- MURA N/A
- 52 Week Low
- TOP $1.00
- MURA $0.95
- 52 Week High
- TOP $3.33
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- TOP 34.31
- MURA 50.82
- Support Level
- TOP $1.03
- MURA $2.06
- Resistance Level
- TOP $1.07
- MURA $2.10
- Average True Range (ATR)
- TOP 0.05
- MURA 0.02
- MACD
- TOP -0.00
- MURA -0.00
- Stochastic Oscillator
- TOP 20.37
- MURA 50.00
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.